You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

DUAC: HELPING PATIENTS WITH ACNE FOR 15 YEARS

Duac: helping patients for 15 years

When it comes to choosing a first-line treatment for patients with mild to moderate acne, you need something they can rely on.

Once-daily gel

Duac has been helping patients with mild to moderate acne for 15 years

  • Duac is a fixed-dose combination that brings together clindamycin and benzoyl peroxide, in a simple and convenient once-daily gel 1
  • Duac has proven efficacy and tolerability in clinical studies vs. monotherapy and other comparable fixed-dose combinations 3-6 and is supported by 15 years of pharmacovigilance data 12
Provides improvements in lesions

Delivering visible improvements for patients

  • Duac provides comparable improvements in inflammatory and noninflammatory lesions to adapalene/BPO at week 12, with a faster time to treatment success* and favourable tolerability 4
  • A higher number of patients are satisfied† with Duac than with adapalene/BPO and fewer patients miss applications due to tolerability issues or adverse events during the first few weeks of treatment 47
Favourable tolerability

Duac is a trusted fixed-dose combination

  • Duac: the European Dermatology Forum (EDF) acne treatment guidelines give a high strength recommendation for fixed-dose combinations of benzoyl peroxide (BPO) + clindamycin (such as Duac) or BPO + adapalene as therapy for the treatment of mild to moderate papulopustular acne 8
  • The strength of recommendation considered all aspects of the treatment decision, such as efficacy, safety, patient preference, and the reliability of the existing body of evidence 8

* Defined as an improvement of 2 grades or more from baseline on the investigator’s static global scale assessment (ISGA) scale (a 6-point scale [0=clear skin with no inflammatory lesions; 5=severe acne with many inflammatory and non-inflammatory lesions and more than a few nodular lesions]) 4
† In two eight-week studies, with a randomized, single-blind, 2-week split-face phase, a higher number of patients were more satisfied with Duac than adapalene/BPO during the first (65.3% vs. 31.9%) and second week of treatment (56.2% vs. 42.5%, no p value has been provided). Both treatments were rated equally effective at reducing acne break outs. Tolerability was significantly better with Duac than adapalene/BPO as reported by investigators and patients (p<0.05).

References:

  1. Duac Once Daily 5% Gel, Summary of Product Characteristics
  2. US FDA website. Drug Approval Packages: Duac. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050741_duac.cfm (Accessed November 2017).
  3. Lookingbill DP et al. J Am Acad Dermatol 1997;37:590–595.
  4. Zouboulis C et al. Cutis 2009;84:223–229.
  5. Langner A et al. JEADV 2007;21:311–319.
  6. Langner A et al. Br J Dermatol 2008;158:122–129.
  7. Green L et al. J Clin Aesthet Dermatol 2012;5:16–24.
  8. Nast A et al. European Dermatology Forum. S3-Guideline for the treatment of acne (Update 2016). Available at: http://www.euroderm.org/edf/index.php/edf-guidelines/category/4-guidelines-acne (Accessed November 2017).

Duac is a registered trademark of the GlaxoSmithKline group of companies.